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Abstract
Short helical peptides combine characteristics of small molecules and large proteins and provide 
an exciting area of opportunity in protein design. A growing number of studies report novel helical 
peptide inhibitors of protein-protein interactions. New techniques have been developed for peptide 
design and for chemically stabilizing peptides in a helical conformation, which frequently 
improves protease resistance and cell permeability. We summarize advances in peptide 
crosslinking chemistry and give examples of peptide design studies targeting coiled-coil 
transcription factors, Bcl-2 family proteins, MDM2/MDMX, and HIV gp41, among other targets.
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Introduction
Of the many protein functions that scientists would like to program and control, binding is 
among the most fundamental. Proteins or other molecules that bind selectively to desired 
targets can be used for investigative molecular biology, as tools to control molecular 
assembly, as diagnostics, or as therapeutics. Proteins or peptides that bind to a target in 
competition with an endogenous partner have high potential for therapeutic development 
because many protein-protein interactions (PPIs) are misregulated in disease.
Despite some successes, it is broadly recognized that PPIs are difficult to control using small 
molecules.[1] Small molecules may not find purchase in the sometimes-flat interfacial 
surfaces of proteins, and low-molecular weight compounds may not compete effectively 
with interactions that bury a large surface area. Developing protein-based PPI inhibitors also 
faces obstacles. For example, antibodies can be engineered to bind with high affinity to 
many targets, but these molecules are currently limited to extracellular applications. The 
large size of antibodies is also non-ideal for applications that require deep tumor penetration 
or fast clearance, and the immunoglobulin fold may not be optimal for binding narrow, hard-
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to-access epitopes. Intermediate between large proteins and small molecules, peptides hold 
promise for inhibiting protein interactions both inside and outside living cells. The cell 
delivery problem is more tractable for peptides than for antibodies, and peptides have the 
flexibility to adopt diverse conformations and make a variety of chemical contacts. The 
diversity of synthetic peptides can be increased by incorporation of non-natural side chains 
or other chemical modifications.
Designing a short peptide to bind to a specific target-protein interaction surface poses a 
difficult problem. One approach is to design synthetic molecules that closely mimic a 
structural element found in a native interface.[2] Ideally, synthetic molecules would improve 
on native interactions to increase potency. The concept of mimicking naturally occurring 
interface structural elements has been explored for decades. Here, we provide an update on 
recent activity developing helical peptide inhibitors of protein-protein interactions. Several 
landmark protein targets of high biomedical importance use helices for binding, including 
the Bcl-2 family of proteins, MDM2/MDMX, and the HIV envelope protein gp41. All of 
these are discussed in this review; representative structures of helix-mediated complexes are 
shown in Fig. 1
The Arora group has surveyed the PDB to identify protein interfaces that include helices.[3] 
Bergey et al. published the Helical Interfaces in Protein-Protein Interactions (HiPP) database 
to compile examples of helix-mediated complexes.[4] HiPP includes information such as the 
length of the helix found at each interface, its contribution to the buried surface area of the 
complex, and an estimate of the energy change for mutation to alanine of each residue in the 
helix. The 2013 release compiles 7308 helices of minimum length 4 residues and average 
length ~13 residues that include at least two residues predicted to contribute at least 1 
kcal/mol each to binding. Arora and colleagues recently moved on to consider interfaces that 
incorporate two interacting helices, and they have proposed and tested chemical linkage 
strategies for stabilizing short coiled-coil tertiary motifs that can potentially disrupt such 
complexes.[5,6]
Below we summarize studies that have used synthetic peptides to mimic and inhibit native 
helix-mediated interactions. The challenges addressed include: Can a native-sequence 
peptide partner be further optimized to improve binding affinity and/or specificity? Can 
synthetic peptides be modified to enhance cell permeability and protease resistance, both of 
which are critical for application of peptides as therapeutics? Can multiple peptide 
properties be optimized simultaneously? Much has been done in this field, and we highlight 
only recent advances. We also limit our treatment to inhibitors based on alpha-amino 
peptides, despite the exciting prospect of using other types of molecules, such as beta-
peptides, as inhibitors.
Methods for improving native peptide sequence and scaffold structure
A short peptide corresponding to a native interfacial structural element can sometimes 
function as an interaction inhibitor. Improving on this simple approach can involve changing 
the sequence and/or altering the scaffold structure to improve peptide properties such as 
binding affinity and specificity, stability, solubility, protease resistance and cell permeability. 
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Peptide library screening and peptide chemical modification are essential tools for these 
tasks.
Library screening can be used to identify high-affinity peptide ligands, with in-cell screening 
presenting an attractive strategy for optimizing peptides for the environment in which they 
must function.[7] Particularly for longer peptides, an element of rational design can help 
focus the search on sequences likely to enhance function. In some design problems it is 
important to consider binding specificity and to improve the affinity of a peptide for one 
target but not for paralogous family members; this is a consideration in many of the case 
studies described below. In this situation, computational methods can be used to evaluate 
both desired and undesired interactions. Using computational optimization to design a 
library is a promising way to combine a rational approach with the power of high-throughput 
screening; Chen and Keating have reviewed advances in computationally guided library 
design.[8]
Short peptides are typically unstructured in solution, which makes them susceptible to 
proteolysis and means that the entropic price of folding must be paid upon binding. 
Furthermore, most unmodified peptides are poorly cell penetrating. Extensive research has 
led to diverse methods for stabilizing peptides in a helical conformation. One strategy is to 
incorporate a helical motif into a larger folded protein scaffold, which can also introduce 
additional favorable inhibitor-target contacts.[9,10] To promote cell entry, however, it is 
preferable to minimize peptide molecular weight. For this reason, many methods have been 
developed to stabilize short peptides in a helical conformation.
Crosslinking to enforce covalent i, i+4 or i, i+7 linkages is a common way to enhance 
helicity. Widely applied methods include lactam bridge formation between lysine and 
aspartate or glutamate, and the more recent and now widespread use of all-hydrocarbon 
stapling (Fig. 2a).[11] Hydrocarbon stapling can impart remarkable structural stability, 
extracellular and intracellular protease resistance, and cell entry via macropinocytosis.[12] 
The stapling modification can enhance or disrupt binding, and extensive optimization of 
linker length and position, as well as fine-tuning of the peptide sequence, is often required. 
Following the successful design of stapled peptides that engage high-profile biomedical 
targets, an increasing number of groups have reported new crosslinking and convenient 
chemistries. For example, Wang et al. demonstrated a facile synthetic platform for two-
component thiol–ene coupling and applied this method to synthesize p53 mimetics that 
selectively induce cell death.[13]
Recent work on chemical crosslinking has included studies of how peptide modifications 
impact cell permeability. Pentelute and coworkers used a perfluorinated aryl linker, attached 
to cysteine residues, to make a peptide inhibitor of the HIV-1 capsid assembly polyprotein 
(Fig. 2b).[14] The lipophilicity of the perfluorinated moieties improved cell uptake. The 
chemistry of cysteine arylation that was used operates on unprotected peptides made of 
standard amino acids and does not require a metal catalyst.
Muppidi et al. used a series of distance-matched aryl and vinylaryl groups to link i, i+ 7 
cysteine residues by alkylation and found a correlation between cell permeability and 
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hydrophobicity (Fig. 2b).[15] This study highlighted the importance of factors beyond 
helicity and binding affinity. Spring and coworkers developed an i, i+ 7 double-click stapling 
technique (Fig. 2c) and made a set of peptides with nanomolar affinity to MDM2.[16] 
However, the tightest-binding peptide showed poor uptake and was not active in a cellular 
p53 reporter assay. Modification of the dialkynyl linkers to add net positive charge resulted 
in improved cell entry.
New helix-stabilizing crosslinkers provide opportunities for further functional elaboration at 
the modification site. For example, Vasco et al. demonstrated that the Ugi reaction operating 
on modified side chains can both stabilize an α-turn and introduce exocyclic N-
functionalization at the resulting lactam bridge.[17] In another example, the acetone-linked 
bridge reported by Assem et al. has been shown to enhance helical secondary structure when 
introduced between peptide side-chain nucleophiles such as thiols.[18] In addition to 
stabilizing helical structures, the ketone moiety in the linker can be modified with diverse 
molecular tags by oxime ligation. These chemistries provide additional opportunities to 
improve both peptide-target interactions and other peptide properties.
Switchable crosslinkers provide the ability to control peptide helicity with light or other 
inputs. The strategy of connecting cysteine residues with a crosslinker containing 
azobenzene has been used to provide photocontrol in several systems.[19,20] Martín-Quíros 
et al. recently developed a helical peptide inhibitor of the interaction between β-arrestin and 
β-adaptin for which the inhibition constant differs by ~12.6 fold in the presence vs. absence 
of light.[19] Interestingly, Belotto et al. have shown how peptides including azobenze 
crosslinkers can be selected for binding using phage display, which may lead to exciting 
applications in helical peptide design.[21] In an example of redox switching, Miller et al. 
developed a reversible stapling system in which peptide conformation can be controlled 
through thiol oxidation.[22] Another example of a reversible stapling strategy is the 
formation of oxime linkages through the chemoselective reaction between aminooxy- and 
aldehyde-functionalized amino acids (Fig. 2a).[23] Switchable peptide inhibitors are useful 
for probing the relation between protein structure and interaction, and potentially for turning 
interactions on and off in a complex environment.
Coiled-coil transcription factors
The simplest helix-mediated interaction is a coiled coil. No other structural elements are 
involved in these supercoiled bundles of 2 or more helices that can be aligned either parallel 
or antiparallel. Coiled coils are prevalent in the proteome and mediate many interactions 
important in disease. Designing a replacement for one of the native helices in a coiled coil is 
an attractive strategy for making an inhibitor, and this has been demonstrated, e.g. for bZIP 
and bHLHzip transcription factors (Fig. 1a) and recently for a coiled coil in the 
juxtamembrane region of epidermal growth factor receptor.[24–28]
The Keating lab designed binding partners for 19 human bZIP transcription factors that 
dimerize via a coiled coil (Fig. 1a),[28,29] using a computational strategy that 
simultaneously optimized interactions with the desired target while destabilizing interactions 
with related off-target proteins.[30] Chen et al. and Reinke et al. extended this approach to 
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viral bZIP targets.[31,32] More recently, Kaplan et al. further optimized first-generation 
designs that target human transcription factors including the disease-related FOS and XBP1 
proteins.[33] The strategy was to improve affinity by altering the choice of surface residues 
in order to increase peptide helicity. This approach consistently gave tighter-binding 
peptides. But introducing charged residues on the surface altered the originally designed 
specificity patterns, sometimes leading to undesired off-target interactions and highlighting 
the difficulty of simultaneously optimizing affinity and specificity.
Computational design of coiled-coil partners requires a scoring function that can evaluate 
binding to desired targets and undesired off-targets. Grigoryan et al. used a hybrid function 
that blends residue-level interaction terms measured experimentally with other terms derived 
from molecular modeling.[34] Incorporating experimental terms was critical for good 
performance. Now that large data sets have been generated to describe some classes of PPIs, 
it has become possible to bias computational scoring functions even more using 
experimental observations. Potapov et al. recently reported the use of 4549 bZIP 
dimerization affinities to train a scoring function for bZIP interaction prediction.[35,36] The 
new scoring method showed significant improvement over other functions and was used to 
design selective helical peptide inhibitors of bZIP proteins JUN, XBP-1, ATF4 and ATF5.
Arndt and coworkers have developed and applied in-cell library screening methods to 
generate peptide inhibitors of coiled-coil interactions involving FOS/JUN and cMyc.[26,27] 
More recently this group reported the design of peptides that bind to (1) the coiled-coil 
domain of AF10, a transcription factor involved in a leukemia-inducing chromosomal 
translocation and (2) the coiled-coil domain of microphthalmia-associated transcription 
factor (MITF).[37,38] These peptides were engineered by screening libraries designed to 
introduce variation at interfacial sites known to be important for interaction. Using phage 
display or a “hitchhiker” translocation (HiT) complementation assay that made it possible to 
select simultaneously for expression, solubility and binding in Escherichia coli, the authors 
were able to identify peptides with high affinity for their targets. The structure of a designed 
peptide bound to the MITF coiled coil shows details of the design-target interaction (Fig. 
1a).[37]
Rao et al. investigated the truncation and crosslinking of designed inhibitors of FOS.[39] 
Starting with a previously engineered peptide binder of FOS, JunWCANDI, these authors 
showed that dissociation constants < 10 µM could be retained when peptides were shortened 
by 12 residues and stabilized by introduction of 2 or 3 lactam crosslinks. A crosslinked 
peptide of this type retained preferential binding to FOS over JUN, but the binding 
specificity with respect to other related bZIP proteins was not tested. It will be important to 
establish whether designed helical peptides retain broadly selective binding when shortened.
Bcl-2 family proteins
Members of the anti-apoptotic Bcl-2 family of proteins, which include paralogs Bcl-xL, 
Bcl-2, Bcl-w, Mcl-1 and Bfl-1, are overexpressed in many cancers and can bind to and 
inhibit the function of pro-death proteins that include a helical Bcl-2 homology 3 (BH3) 
motif. Small molecules that mimic BH3 motifs can block protein interactions with Bcl-xL 
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and Bcl-2 and induce tumor regression; such molecules are in clinical trials.[40] Inhibiting 
Bcl-xL is toxic to platelets, however, and it has proven difficult to identify selective and 
bioactive antagonists of other Bcl-2 family members such as Mcl-1, which is frequently 
overexpressed in cancers.[41] Designed peptides hold promise for this application.
Walensky et al. showed in 2004 that a helically constrained 23-residue peptide 
corresponding to the BH3 region of pro-apoptotic BID binds tightly to Bcl-xL and also 
activates apoptosis in cell culture and in mice.[42] Subsequent work led to additional Bcl-2 
family interaction inhibitors made by crosslinking peptides corresponding to native BH3 
sequences.[43,44] Examples include an inhibitor of Mcl-1 derived from the sequence of the 
Mcl-1 BH3 motif itself and an inhibitor of Mcl-1 made by bis-aryl linkage of cysteine 
residues introduced into the Noxa BH3 motif. Variants of the BH3 motif from BIM (Fig. 1b) 
have also been crosslinked for cell studies.[45–47]
Many crosslinked BH3 peptides have enhanced helicity, increased protease resistance, and 
an improved ability to enter cells. Some, but not all, helically stabilized peptides show 
improvements in binding affinity. Interestingly, closing of the crosslink is not always 
required for these enhancements.[48] Important lessons derived from work on crosslinked 
BH3-like peptides are that not all crosslinks are equivalently effective at increasing helicity 
or binding, increased helicity is not a guarantee of increased binding, the properties of 
peptides that determine their cell permeability are not yet thoroughly understood, and any 
kind of modification has to be considered as an additional design variable. Also, the precise 
length and sequence of a peptide is important. Changing the sequence by just a residue or 
two can have a large impact on binding, as might be expected for such short peptide binders.
[46,48]
Native BH3 motif sequences may not be optimal as Bcl-2 family inhibitors. Notably, BIM 
and BID, on which many peptide inhibitors have been modeled, bind promiscuously to all 
members of the Bcl-2 family. More selective inhibitors may be required to avoid unwanted 
toxicity. In our lab, we have developed peptides that have high affinity for just one human 
family member, targeting Bcl-xL, Mcl-1 or Bfl-1.[49,50] Foight and Keating reported the 
design of selective inhibitors of Bcl-2 family proteins from Epstein-Barr virus (BHRF1) and 
Kaposi’s sarcoma virus (KS-Bcl-2).[51] The approach in these studies was to use 
experimental data for many mutations, and in some cases structure-based modeling, to 
design focused libraries of ~107 high priority binding candidates. These libraries were 
screened for interaction with the target in the presence of competing paralogs using either 
yeast-surface or bacterial-surface display. The resulting peptides have low nanomolar 
dissociation constants and bind preferentially to the intended target over related proteins. 
The design process was guided in some cases by a novel structure-based scoring model.
[52,53]
Although BH3-like peptides do not typically enter cells without modification, their efficacy 
can be tested in a cellular context using the technique of BH3 profiling.[54] In this assay, 
permeabilized cells are treated with peptides, and inhibitory activity is assayed by 
monitoring the loss of mitochondrial outer membrane integrity that occurs when anti-
apoptotic factors are blocked. BH3 profiling can be used as a diagnostic to determine the 
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Bcl-2 dependencies of primary patient cells that resist chemotherapy. It is encouraging that 
designed helical peptide inhibitors targeting Bcl-xL and Mcl-1 show good potency and 
selectivity in BH3 profiling assays.[50,55] Peptides active in this assay are excellent 
candidates for further therapeutic development.
MDM2 and MDMX
MDM2 and MDMX bind to a short helical region of the tumor suppressor p53 and inhibit its 
function both directly, by blocking activation activity, and by promoting ubiquitination that 
leads to degradation. The inhibitory interaction of MDM2 and MDMX with p53 is a “holy 
grail” drug target and, excitingly, designed alpha helices that block this interaction show 
promising results in pre-clinical testing. Earlier work designing MDM2 and/or MDMX 
inhibitors either used library methods (e.g. phage display screening) to identify peptide 
sequences that bound with high affinity, or introduced helix modifications such as 
hydrocarbon staples to stabilize short segments of p53 itself. Not surprisingly, the most 
effective inhibitors so far discovered have come from combining these enhancements.
In parallel efforts, a team from Aileron Therapeutics and a group at the p53 Laboratory in 
Singapore took different phage-display optimized peptides,[56,57] introduced a hydrocarbon 
staple to stabilize helical conformations, and mutated the resulting molecules to improve 
pharmacologic properties while improving or retaining tight binding. In the Aileron effort, 
hydrocarbon stapling immediately improved peptide binding to both MDM2 and MDMX.
[58] Further intensive optimization, which involved introducing a cyclobutylmethyl side 
chain, altering the peptide length, and tuning solubility, led to ATSP-7041. This molecule 
binds MDM2 and MDMX with dissociation constants < 5 nM, enters cells, and re-activates 
p53 signaling. A crystal structure shows how 2 large, hydrophobic side chains and one 
tyrosine make critical contacts with the p53-binding groove, and how the hydrophobic atoms 
of the stapled crosslink also engage the protein target MDMX (Fig. 1c). Pharmaceutical 
companies have invested heavily to advance ATSP-7041 to the clinic. Truncation and 
stapling of another MDM2-binding peptide by Brown et al. failed to improve affinity, but 
stapled peptides showed dramatically increased activity in p53 activation assays.[59] The 
intensive effort and many iterations of design required to arrive at biologically active stapled 
peptide inhibitors of MDM2 and MDMX provide a cautionary tale: Developing 
pharmaceutical quality modified peptides requires much of the same slow, steady 
optimization as does traditional small-molecule discovery, and multiple molecular properties 
must be simultaneously considered. Tan et al. recently published a cellular thermal shift 
assay that may make it easier to optimize modified peptides for both cell entry and tight 
binding in a complex environment.[60]
In another strategy for making helical MDM2-targeting peptides, Lu and coworkers 
published optimization of D-peptide inhibitors originally identified by mirror-image phage 
display.[61,62] In mirror-image display, phage that display L-peptides are panned against a 
version of MDM2 synthesized out of D-amino acids; the hits are then synthesized with L-
amino acids to target the native protein. Structure-guided optimization led to introduction of 
fluorine and tri-fluoromethyl groups on aromatic residues that increased hydrophobic 
contacts, yielding a ligand with an affinity of 220 pM.
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Other targets
Helical peptide inhibitors targeting many other biomedically important proteins have been 
reported. Prominent among these is the HIV envelope protein gp41, which includes two 
helical segments, N-terminal and C-terminal, each of which can potentially be used as a 
starting point for inhibitor design. Enfuvirtide is an approved peptide drug derived from the 
C-terminal helical segment. The drug blocks membrane fusion to inhibit viral entry.[63] The 
half-life of enfuvirtide is short, however, and the peptide is bound by patient antibodies. 
Also, some HIV strains are resistant to the drug. Recent design efforts to improve the 
properties of gp41-targeting inhibitors have focused on altering the peptide sequence or 
stabilizing the folded structure of inhibitors. Shi et al. used structure-based modeling to 
design peptides with low sequence identity to enfuvirtide,[64] and these were later improved 
to give molecule AP3. AP3 is effective against resistant strains and non-reactive with patient 
antibodies.[65] Other recent work on HIV gp41 inhibitor design focused on the N-terminal 
portion of the gp41 ectodomain and on stabilizing a helical trimer sub-structure. Crespillo et 
al. engineered a single-chain construct to mimic the native gp41 N-segment homotrimer.[66] 
The resulting protein, which is ~170 residues long, has an up-up-down arrangement of 
helices combined in a single chain to present a binding surface similar to the native 
homotrimer. The engineered pseudo-trimer is active as a fusion inhibitor. To accomplish a 
similar objective, Chu et al. reversed the connectivity of N- and C-terminal helical segments 
in gp41, making a trimer of ~80 residue peptides in which it was possible to adjust the 
amount of the N-terminal binding surface exposed. This strategy was used to make a low-
nanomolar inhibitor of fusion.[67] Ebola and other enveloped viruses can potentially be 
targeted using similar design strategies.[68]
A large number of other proteins have been successfully targeted using short, helical 
peptides; it is impractical to list them all in this short review. Recent advances indicate that 
in many cases where there is structural or biochemical evidence for a helix-mediated 
protein-protein interaction, a native helical segment can be made as a constrained peptide 
that works as an inhibitor of function. Examples include peptides that bind GTPases Rab and 
KRAS, insulin receptor substrate 1 (important in phosphatidylinositol 3-kinase α signaling), 
epidermal growth factor receptor, and the Plasmodium falciparum myoA tail interacting 
protein.[25,69–72] Interestingly, myoA tail interacting protein surrounds its helical peptide 
ligand, but structures show how peptides including either hydrocarbon staples or a hydrogen 
bond surrogate can be accommodated in this constrained binding site (Fig. 1d).[72] Cell-
permeable peptide inhibitors of the type-I regulatory domains of protein kinase A were 
recently designed by adding a hydrocarbon staple to a previously engineered peptidic 
inhibitor.[73]
Conclusions
The alpha helix is a simple structural motif, yet the number of possible short helical peptide 
sequences and conformations – particularly when one considers non-natural amino acids – is 
vast. Adding to this the possibility of modifying peptides with extra-structural elements such 
as crosslinkers increases the design space by many more orders of magnitude. In the face of 
such a massive search problem, it is fortunate that for many protein-protein interactions a 
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helical peptide derived from a native protein sequence provides an excellent starting point 
for inhibitor design. Furthermore, given that there is little reason to assume that native-
sequence peptides have optimal binding affinity, binding selectivity, solubility, cell delivery 
or pharmacokinetic properties for a given purpose, the large space of possible modifications 
provides opportunities. The design challenge that confronts the field is to efficiently improve 
on native-sequence inhibitors to accelerate discovery.
We highlight three areas of importance for advancing helical peptide design and 
development. First, computational modeling can be more extensively exploited to guide 
rational improvement of inhibitors and informed selection of peptide crosslinking positions. 
Structural information is available for many of the targets discussed above, yet 
computationally aided structure analysis is infrequently used in inhibitor optimization. 
Modeling can be applied to identify and rank candidate affinity enhancing mutations and to 
evaluate potential crosslinkers.[74] The work of Joseph et al. provides precedent in this area.
[75] These authors used molecular modeling to design candidate new stapled peptides for 
binding to Mcl-1. Lama et al. have also used simulation to guide design of helical peptide 
inhibitors of EIF4E.[76] We expect this type of structure-guided design to be an area of 
growth going forward.
Improvements in library screening are also needed. For example, computational methods can 
be used to design custom libraries enriched in candidate high-affinity or high-specificity 
binders. Such methods can incorporate data from structural analyses and from prior 
experimental work, as we have shown in our studies of Bcl-2 proteins.[50,51] On the 
experimental side, library screening has so far been done on unmodified peptides made of 
natural amino acids (when using genetic encoding) or mixtures of natural and non-natural 
amino acids (when constructing libraries using chemical synthesis). But it will be important 
to adapt library methods to screen peptides that include chemical modifications that enhance 
helicity and cell entry. Towards this end, we recently developed one-bead-one-compound 
library methods that can be used to optimize stapled peptides (Rezaei Araghi and Keating, 
submitted). Das et al. have synthesized and screened libraries of cyclized peptides.[77] Their 
techniques provide synthetic flexibility to incorporate non-natural amino acids, allowing for 
post-synthesis modification of ~2 million sequences using Cu-catalyzed azide–alkyne 
cycloaddition or ring-closing metathesis. Screening such libraries led to the discovery of 
high-affinity ligands for a wide variety of protein targets.[77] Further advances of this type 
are needed to enable high-throughput screening of large libraries constructed with diverse 
chemistries.
Finally, our understanding of basic sequence-structure-function relationships for constrained 
peptide inhibitors remains somewhat primitive. As larger amounts of data are accumulated, 
and more structures are solved, it will be important to critically evaluate the properties of 
peptides that enhance binding and cell uptake and use this analysis to drive improvements. 
In-depth biophysical analysis is often neglected in the understandable rush to generate 
inhibitors that can help patients. But a better understanding of the molecular mechanisms of 
binding for modified helices will ultimately benefit the field and improve our capabilities in 
design.
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Figure 1. 
Complexes including designed helical peptides. (a) At left, native bZIP complex FOS:JUN 
bound to DNA (1FOS),[28] which has been the target of many design studies.[24,26,30] At 
right, structure 4C7N shows a designed peptide binding to the coiled coil from bHLHzip 
transcription factor MITF. (b) Mcl-1 SAHBD engages Mcl-1 in the canonical BH3-binding 
groove. The hydrocarbon staple contributes additional contacts at the perimeter of the core 
interaction site (3MK8).[44] (c) Peptide-based ATSP-7041 bound to MDMX shows how the 
hydrocarbon staple contributes to the interaction (5N5T).[58] (d) A designed peptide 
corresponding to a segment of myoA is stabilized by a hydrocarbon staple and 
accommodated in the myoA tail interacting protein binding site (4MZK).[72] Target proteins 
are grey, with designed peptides in green and any helix modifying crosslinks highlighted in 
red.
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Figure 2. 
Chemical modifications for stabilizing alpha helical structure in short peptides. a) Direct 
side chain stapling of amino acids at positions i, i + 4. All-hydrocarbon stapling using α,α-
disubstituted amino acids bearing olefinic side-chains, lactamization of peptides containing 
lysine and glutamate or aspartate residues, and oxime stapling of peptides containing amino 
acids bearing aminooxy and aldehyde side chains. b) and c) Side chain stapling via 
functionalized linkers. b) Bis-arylation of two cysteine residues at positions i, i + 4 with 
hexafluorobenzene and crosslinking of peptides containing cysteines at positions i, i + 7 with 
vinylaryl linkage. c) Double-click stapling of peptides containing two azidoornithine 
residues at positions i, i + 7 with a dialkynyl linker.
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